Antibody Drug Conjugate Market Research Report by Mechanism of Action, Drugs, Technology, Application, End User, Region - Global Forecast to 2027 - Cumulative Impact of COVID-19

The Global Antibody Drug Conjugate Market size was estimated at USD 4,378.75 million in 2021 and expected to reach USD 5,076.28 million in 2022, and is projected to grow at a CAGR 16.10% to reach USD 10,727.58 million by 2027.

Market Statistics:
The report provides market sizing and forecast across 7 major currencies - USD, EUR, JPY, GBP, AUD, CAD, and CHF. It helps organization leaders make better decisions when currency exchange data is readily available. In this report, the years 2018 and 2020 are considered as historical years, 2021 as the base year, 2022 as the estimated year, and years from 2023 to 2027 are considered as the forecast period.

Market Segmentation & Coverage:
This research report categorizes the Antibody Drug Conjugate to forecast the revenues and analyze the trends in each of the following sub-markets:

Based on Mechanism of Action, the market was studied across CD30 Antibodies and HER2 Antibodies.

Based on Drugs, the market was studied across Adcetris and Kadcyla.

Based on Technology, the market was studied across Cleavable Linker, Linkerless, and Non-cleavable Linker.

Based on Application, the market was studied across Blood Cancer, Breast Cancer, Leukemia, Lymphoma, Multiple Myeloma, and Urothelial Cancer & Bladder Cancer.

Based on End User, the market was studied across Academic Research Institutes, Biopharmaceutical Companies, Biotechnology Companies, Hospitals, Others, and Specialized Cancer Centers.

Based on Region, the market was studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

Cumulative Impact of COVID-19:
COVID-19 is an incomparable global public health emergency that has affected almost every industry, and the long-term effects are projected to impact the industry growth during the forecast period. Our ongoing research amplifies our research framework to ensure the inclusion of underlying COVID-19 issues and potential paths forward. The report delivers insights on COVID-19 considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The updated study provides insights, analysis, estimations, and forecasts, considering the COVID-19 impact on the market.

Cumulative Impact of 2022 Russia Ukraine Conflict:
We continuously monitor and update reports on political and economic uncertainty due to the Russian invasion of Ukraine. Negative impacts are significantly foreseen globally, especially across Eastern Europe, European Union, Eastern & Central Asia, and the United States. This contention has severely affected lives and livelihoods and represents far-reaching disruptions in trade dynamics. The potential effects of ongoing war and uncertainty in Eastern Europe are expected to have an adverse impact on the world economy, with especially long-term harsh effects on Russia.This report uncovers the impact of demand & supply, pricing variants, strategic uptake of vendors, and recommendations for Antibody Drug Conjugate market considering the current update on the conflict and its global response.

Competitive Strategic Window:
The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies to help the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. It describes the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth during a forecast period.

FPNV Positioning Matrix:
The FPNV Positioning Matrix evaluates and categorizes the vendors in the Antibody Drug Conjugate Market based on Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.

Market Share Analysis:
The Market Share Analysis offers the analysis of vendors considering their contribution to the overall market. It provides the idea of its revenue generation into the overall market compared to other vendors in the space. It provides insights into how vendors are performing in terms of revenue generation and customer base compared to others. Knowing market share offers an idea of the size and competitiveness of the vendors for the base year. It reveals the market characteristics in terms of accumulation, fragmentation, dominance, and amalgamation traits.

Competitive Scenario:
The Competitive Scenario provides an outlook analysis of the various business growth strategies adopted by the vendors. The news covered in this section deliver valuable thoughts at the different stage while keeping up-to-date with the business and engage stakeholders in the economic debate. The competitive scenario represents press releases or news of the companies categorized into Merger & Acquisition, Agreement, Collaboration, & Partnership, New Product Launch & Enhancement, Investment & Funding, and Award, Recognition, & Expansion. All the news collected help vendor to understand the gaps in the marketplace and competitor’s strength and weakness thereby, providing insights to enhance product and service.

Company Usability Profiles:
The report profoundly explores the recent significant developments by the leading vendors and innovation profiles in the Global Antibody Drug Conjugate Market, including Abbvie Inc., ADC Therapeutics, Agensys, Inc., Astellas Pharma, AstraZeneca, Bayer AG, Celldex Therapeutics Inc., Concortis Biotherapeutics, Daiichi Sankyo Company Ltd., F. Hoffmann-La Roche Ltd., Gilead Sciences, Inc., GlaxoSmithKline Plc, Immunomedics Inc., Novartis AG, Oxford BioTherapeutics, Pfizer, Inc., Sanofi S.A., Seagen, Inc., Seattle Genetics Inc., Synthon Holding B.V., and Takeda Pharmaceutical Company Ltd..

The report provides insights on the following pointers:
1. Market Penetration: Provides comprehensive information on the market offered by the key players
2. Market Development: Provides in-depth information about lucrative emerging markets and analyze penetration across mature segments of the markets
3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments
4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players
5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments

The report answers questions such as:
1. What is the market size and forecast of the Global Antibody Drug Conjugate Market?
2. What are the inhibiting factors and impact of COVID-19 shaping the Global Antibody Drug Conjugate Market during the forecast period?
3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Antibody Drug Conjugate Market?
4. What is the competitive strategic window for opportunities in the Global Antibody Drug Conjugate Market?
5. What are the technology trends and regulatory frameworks in the Global Antibody Drug Conjugate Market?
6. What is the market share of the leading vendors in the Global Antibody Drug Conjugate Market?
7. What modes and strategic moves are considered suitable for entering the Global Antibody Drug Conjugate Market?

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders

2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Increasing prevalence of cancer worldwide
5.1.1.2. Growth in R&D activities and strong product pipeline
5.1.1.3. Surging geriatric population base
5.1.2. Restraints
5.1.2.1. High manufacturing cost of ADC
5.1.3. Opportunities
5.1.3.1. Increasing investment in biopharma R&D
5.1.3.2. Positive prospect in low market penetration nations
5.1.4. Challenges
5.1.4.1. Challenges related to downstream processing of Antibody Drug Conjugate
5.2. Cumulative Impact of COVID-19

6. Antibody Drug Conjugate Market, by Mechanism of Action
6.1. Introduction
6.2. CD30 Antibodies
6.3. HER2 Antibodies

7. Antibody Drug Conjugate Market, by Drugs
7.1. Introduction
7.2. Adcetris
7.3. Kadcyla

8. Antibody Drug Conjugate Market, by Technology
8.1. Introduction
8.2. Cleavable Linker
8.3. Linkerless
8.4. Non-cleavable Linker

9. Antibody Drug Conjugate Market, by Application
9.1. Introduction
9.2. Blood Cancer
9.3. Breast Cancer
9.4. Leukemia
9.5. Lymphoma
9.6. Multiple Myeloma
9.7. Urothelial Cancer & Bladder Cancer

10. Antibody Drug Conjugate Market, by End User
10.1. Introduction
10.2. Academic Research Institutes
10.3. Biopharmaceutical Companies
10.4. Biotechnology Companies
10.5. Hospitals
10.6. Others
10.7. Specialized Cancer Centers

11. Americas Antibody Drug Conjugate Market
11.1. Introduction
11.2. Argentina
11.3. Brazil
11.4. Canada
11.5. Mexico
11.6. United States

12. Asia-Pacific Antibody Drug Conjugate Market
12.1. Introduction
12.2. Australia
12.3. China
12.4. India
12.5. Indonesia
12.6. Japan
12.7. Malaysia
12.8. Philippines
12.9. Singapore
12.10. South Korea
12.11. Taiwan
12.12. Thailand
12.13. Vietnam

13. Europe, Middle East & Africa Antibody Drug Conjugate Market
13.1. Introduction
13.2. Denmark
13.3. Egypt
13.4. Finland
13.5. France
13.6. Germany
13.7. Israel
13.8. Italy
13.9. Netherlands
13.10. Nigeria
13.11. Norway
13.12. Poland
13.13. Qatar
13.14. Russia
13.15. Saudi Arabia
13.16. South Africa
13.17. Spain
13.18. Sweden
13.19. Switzerland
13.20. Turkey
13.21. United Arab Emirates
13.22. United Kingdom

14. Competitive Landscape
14.1. FPNV Positioning Matrix
14.1.1. Quadrants
14.1.2. Business Strategy
14.1.3. Product Satisfaction
14.2. Market Ranking Analysis, By Key Player
14.3. Market Share Analysis, By Key Player
14.4. Competitive Scenario
14.4.1. Merger & Acquisition
14.4.2. Agreement, Collaboration, & Partnership
14.4.3. New Product Launch & Enhancement
14.4.4. Investment & Funding
14.4.5. Award, Recognition, & Expansion

15. Company Usability Profiles
15.1. Abbvie Inc.
15.1.1. Business Overview
15.1.2. Key Executives
15.1.3. Product & Services
15.2. ADC Therapeutics
15.2.1. Business Overview
15.2.2. Key Executives
15.2.3. Product & Services
15.3. Agensys, Inc.
15.3.1. Business Overview
15.3.2. Key Executives
15.3.3. Product & Services
15.4. Astellas Pharma
15.4.1. Business Overview
15.4.2. Key Executives
15.4.3. Product & Services
15.5. AstraZeneca
15.5.1. Business Overview
15.5.2. Key Executives
15.5.3. Product & Services
15.6. Bayer AG
15.6.1. Business Overview
15.6.2. Key Executives
15.6.3. Product & Services
15.7. Celldex Therapeutics Inc.
15.7.1. Business Overview
15.7.2. Key Executives
15.7.3. Product & Services
15.8. Concortis Biotherapeutics
15.8.1. Business Overview
15.8.2. Key Executives
15.8.3. Product & Services
15.9. Daiichi Sankyo Company Ltd.
15.9.1. Business Overview
15.9.2. Key Executives
15.9.3. Product & Services
15.10. F. Hoffmann-La Roche Ltd.
15.10.1. Business Overview
15.10.2. Key Executives
15.10.3. Product & Services
15.11. Gilead Sciences, Inc.
15.11.1. Business Overview
15.11.2. Key Executives
15.11.3. Product & Services
15.12. GlaxoSmithKline Plc
15.12.1. Business Overview
15.12.2. Key Executives
15.12.3. Product & Services
15.13. Immunomedics Inc.
15.13.1. Business Overview
15.13.2. Key Executives
15.13.3. Product & Services
15.14. Novartis AG
15.14.1. Business Overview
15.14.2. Key Executives
15.14.3. Product & Services
15.15. Oxford BioTherapeutics
15.15.1. Business Overview
15.15.2. Key Executives
15.15.3. Product & Services
15.16. Pfizer, Inc.
15.16.1. Business Overview
15.16.2. Key Executives
15.16.3. Product & Services
15.17. Sanofi S.A.
15.17.1. Business Overview
15.17.2. Key Executives
15.17.3. Product & Services
15.18. Seagen, Inc.
15.18.1. Business Overview
15.18.2. Key Executives
15.18.3. Product & Services
15.19. Seattle Genetics Inc.
15.19.1. Business Overview
15.19.2. Key Executives
15.19.3. Product & Services
15.20. Synthon Holding B.V.
15.20.1. Business Overview
15.20.2. Key Executives
15.20.3. Product & Services
15.21. Takeda Pharmaceutical Company Ltd.
15.21.1. Business Overview
15.21.2. Key Executives
15.21.3. Product & Services

16. Appendix
16.1. Discussion Guide
16.2. License & Pricing